MX9501608A - 1h-indol-3-glioxilamidas inhibidoras de spla2. - Google Patents

1h-indol-3-glioxilamidas inhibidoras de spla2.

Info

Publication number
MX9501608A
MX9501608A MX9501608A MX9501608A MX9501608A MX 9501608 A MX9501608 A MX 9501608A MX 9501608 A MX9501608 A MX 9501608A MX 9501608 A MX9501608 A MX 9501608A MX 9501608 A MX9501608 A MX 9501608A
Authority
MX
Mexico
Prior art keywords
indole
spla2 inhibitors
glyoxylamide spla2
glyoxylamide
inhibitors
Prior art date
Application number
MX9501608A
Other languages
English (en)
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9501608A publication Critical patent/MX9501608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describe un nuevo tipo de 1H-indol-3-glioxilamidas junto con el uso de tales compuestos de indol para la inhibicion de la liberacion de ácidos grasos inducida por sPLA2 para el tratamiento de trastornos tales como el choque séptico.
MX9501608A 1994-04-01 1995-03-31 1h-indol-3-glioxilamidas inhibidoras de spla2. MX9501608A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22191694A 1994-04-01 1994-04-01

Publications (1)

Publication Number Publication Date
MX9501608A true MX9501608A (es) 1997-02-28

Family

ID=22829963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9501608A MX9501608A (es) 1994-04-01 1995-03-31 1h-indol-3-glioxilamidas inhibidoras de spla2.

Country Status (29)

Country Link
US (6) US5654326A (es)
EP (5) EP0675110B1 (es)
JP (1) JP3109974B2 (es)
KR (1) KR100368707B1 (es)
CN (1) CN1067054C (es)
AT (2) ATE540923T1 (es)
AU (1) AU688458B2 (es)
BR (1) BR9501404A (es)
CA (1) CA2146097C (es)
CO (1) CO4370099A1 (es)
CZ (1) CZ82295A3 (es)
DE (1) DE69527322T2 (es)
DK (2) DK1950200T3 (es)
ES (2) ES2377223T3 (es)
FI (1) FI114793B (es)
HU (1) HUT72048A (es)
IL (1) IL113210A (es)
MX (1) MX9501608A (es)
MY (1) MY112897A (es)
NO (1) NO304186B1 (es)
NZ (1) NZ270848A (es)
PE (1) PE18696A1 (es)
PL (1) PL180523B1 (es)
PT (1) PT675110E (es)
RU (1) RU2128169C1 (es)
SI (1) SI0675110T1 (es)
TW (1) TW383302B (es)
UA (1) UA47387C2 (es)
ZA (1) ZA952693B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA47387C2 (uk) * 1994-04-01 2002-07-15 Елі Ліллі Енд Компані 1H-ІНДОЛ-3-ГЛІОКСИЛАМІДИ ЯК ІНГІБІТОРИ sPLA<sub>2</sub> ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ
JPH08193074A (ja) * 1994-11-18 1996-07-30 Nippon Bayeragrochem Kk 除草性１−シクロプロピルテトラゾリノン類
KR100436812B1 (ko) * 1995-01-06 2004-08-31 도레이 가부시끼가이샤 벤젠축합헤테로환유도체및그유도체를유효성분으로함유하는의약조성물
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
EP0987250A4 (en) * 1997-02-20 2000-12-06 Shionogi & Co INDOLDICARBONIC ACID DERIVATIVES
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
AU9123198A (en) * 1997-08-28 1999-03-16 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
EP1039911B1 (en) * 1997-10-27 2005-05-25 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1043991A4 (en) * 1997-11-14 2005-02-02 Lilly Co Eli TREATMENT OF ALZHEIMER DISEASE
AU1405899A (en) * 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
IL137719A0 (en) * 1998-02-25 2001-10-31 Genetics Inst Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
CN1299277A (zh) * 1998-03-03 2001-06-13 盐野义制药株式会社 含有磷脂酶抑制剂[[3－(2－氨基－1,2－二氧乙基)－2－乙基－1(苯甲基)－1h－吲哚－4－基]氧基]乙酸钠的药用组合物
JP4412521B2 (ja) 1998-03-31 2010-02-10 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CA2326505A1 (en) * 1998-04-17 1999-10-28 Nancy Kay Harn Process for preparing 4-hydroxy indole, indazole and carbazole compounds
US6407261B1 (en) 1998-04-17 2002-06-18 Eli Lilly And Company Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
AU3656299A (en) * 1998-05-01 1999-11-23 Eli Lilly And Company Spla2 inhibitor compounds for treatment of disease
PL344571A1 (en) * 1998-05-01 2001-11-05 Lilly Co Eli Spla2
CA2332528A1 (en) 1998-05-21 1999-11-25 Shionogi & Co., Ltd. Pyrrolo[1,2-b]pyridazine spla2 inhibitory
EP1100493A4 (en) 1998-08-03 2001-10-24 Lilly Co Eli SPLA 2 INHIBITORS? OF THE INDOLTYPS
DE69931496T2 (de) * 1998-08-03 2006-11-23 Eli Lilly And Co., Indianapolis INDOLVERBINDUNGEN ALS sPLA2 INHIBITOREN
AU6240099A (en) 1998-08-24 2000-03-14 Susan E Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
US6576654B1 (en) 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
DZ2771A1 (fr) * 1998-10-09 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
CA2346334A1 (en) 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
US20030149000A1 (en) * 1998-11-10 2003-08-07 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
EP1214041A2 (en) * 1998-12-21 2002-06-19 Eli Lilly And Company Combination therapy for the treatment of sepsis
EP1144305A4 (en) * 1998-12-22 2004-11-10 Lilly Co Eli NEW sPLA 2 INHIBITORS
ATE247119T1 (de) 1998-12-22 2003-08-15 Lilly Co Eli Substituierte pyrroloindole
US6380397B1 (en) 1999-04-15 2002-04-30 Eli Lilly And Company Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
ATE350367T1 (de) * 1999-07-19 2007-01-15 Lilly Co Eli Spla2 inhibitoren
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
JP4636522B2 (ja) 1999-08-02 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環式化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
EP1220839B1 (en) * 1999-09-20 2006-12-06 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
AU1304801A (en) 1999-11-15 2001-05-30 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect
WO2001044185A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
AU2050001A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Synthesis of indole-containing spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
AU2728301A (en) * 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
AU4599601A (en) * 2000-01-07 2001-07-16 Eli Lilly And Company Substituted tricyclics
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
JP2003525901A (ja) * 2000-03-09 2003-09-02 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターによる腎臓機能障害の治療方法
BR0002188A (pt) * 2000-03-30 2001-11-13 Brasil Compressores Sa Processo de formação do pacote de lâminasmetálicas de estator de motor elétrico e pacotede lâminas metálicas
AU2001252922A1 (en) * 2000-04-19 2001-11-07 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
TW583000B (en) * 2000-06-29 2004-04-11 Shionogi & Co X-type sPLA2 inhibitor as a cancer therapeutical agent
WO2002000257A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes a la maladie d'alzheimer
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
WO2002000256A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cirrhosis
BR0112460A (pt) * 2000-07-14 2003-07-22 Lilly Co Eli Método para tratamento de sépsis
AU2001280461A1 (en) * 2000-08-04 2002-02-18 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
DE60126831D1 (de) * 2000-12-18 2007-04-05 Lilly Co Eli Benz(g)indole und deren verwendung als spla2 inhibitoren
TWI314457B (es) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
TWI323658B (en) 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
JP2009517341A (ja) * 2005-11-03 2009-04-30 イリプサ， インコーポレイテッド Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
AU2006311851A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-A2 inhibitors
US20090318492A1 (en) * 2005-11-03 2009-12-24 Han-Ting Chang Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
MX2008005666A (es) * 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
KR101269393B1 (ko) * 2008-04-28 2013-05-29 아사히 가세이 파마 가부시키가이샤 페닐프로피온산 유도체 및 이의 용도
WO2010081022A1 (en) * 2009-01-08 2010-07-15 Anthera Pharmaceuticals, Inc. Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
CN101838232B (zh) * 2009-07-07 2012-02-22 爱斯医药科技(南京)有限公司 Varespladib的制备方法
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
CN108463221A (zh) * 2015-08-31 2018-08-28 迪亚库雷特公司 吲哚类化合物刺激免疫***的用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2825743A (en) 1955-08-30 1958-03-04 Celanese Corp Catalytic hydrogenation of unsaturated aldehydes and ketones
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
GB1089071A (en) 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
NL287416A (es) 1964-04-25
US3449363A (en) 1966-12-22 1969-06-10 American Cyanamid Co 3-substituted 4-trifluoromethyl indoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
US3691194A (en) * 1970-07-30 1972-09-12 Little Inc A 3-indole-glyoxamides
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
US4397850A (en) 1981-10-07 1983-08-09 Sandoz, Inc. Isoxazolyl indolamines
US4552876A (en) * 1984-07-09 1985-11-12 Usv Pharmaceutical Corp. Bisbenzoxazines and pharmaceutical use
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
NZ234883A (en) * 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
US5334719A (en) * 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
UA47387C2 (uk) * 1994-04-01 2002-07-15 Елі Ліллі Енд Компані 1H-ІНДОЛ-3-ГЛІОКСИЛАМІДИ ЯК ІНГІБІТОРИ sPLA<sub>2</sub> ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
HUP9903671A3 (en) * 1995-12-14 2001-11-28 Merck & Co Inc Antagonists of gonadotropin releasing hormone, pharmaceutical compositions and process for producing them
PL327132A1 (en) 1995-12-14 1998-11-23 Merck & Co Inc Antagonists of the gonadotrophin liberating hormone
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors

Also Published As

Publication number Publication date
DK0675110T3 (da) 2002-10-07
PT675110E (pt) 2002-11-29
CO4370099A1 (es) 1996-10-07
CA2146097A1 (en) 1995-10-02
NO304186B1 (no) 1998-11-09
EP1081135A2 (en) 2001-03-07
EP0675110A1 (en) 1995-10-04
ATE540923T1 (de) 2012-01-15
RU2128169C1 (ru) 1999-03-27
PL307951A1 (en) 1995-10-02
IL113210A0 (en) 1995-06-29
NO951252L (no) 1995-10-02
FI114793B (fi) 2004-12-31
KR950032117A (ko) 1995-12-20
HU9500957D0 (en) 1995-05-29
IL113210A (en) 2001-01-28
MY112897A (en) 2001-10-31
RU95104885A (ru) 1997-04-27
DE69527322D1 (de) 2002-08-14
ATE220394T1 (de) 2002-07-15
PL180523B1 (pl) 2001-02-28
EP1081135A3 (en) 2003-11-05
AU688458B2 (en) 1998-03-12
US6433001B1 (en) 2002-08-13
EP1197484A2 (en) 2002-04-17
AU1621795A (en) 1995-10-12
NO951252D0 (no) 1995-03-31
JPH07285933A (ja) 1995-10-31
CZ82295A3 (en) 1995-12-13
US5919943A (en) 1999-07-06
UA47387C2 (uk) 2002-07-15
JP3109974B2 (ja) 2000-11-20
US5733923A (en) 1998-03-31
ES2377223T3 (es) 2012-03-23
US6175021B1 (en) 2001-01-16
FI951553A0 (fi) 1995-03-31
PE18696A1 (es) 1996-05-30
NZ270848A (en) 1997-05-26
DK1950200T3 (da) 2012-04-10
US5919810A (en) 1999-07-06
ZA952693B (en) 1996-09-30
EP2341045A1 (en) 2011-07-06
ES2179088T3 (es) 2003-01-16
CN1114310A (zh) 1996-01-03
CA2146097C (en) 2000-03-21
FI951553A (fi) 1995-10-02
EP0675110B1 (en) 2002-07-10
CN1067054C (zh) 2001-06-13
EP1950200A1 (en) 2008-07-30
US5654326A (en) 1997-08-05
DE69527322T2 (de) 2003-02-27
SI0675110T1 (en) 2002-12-31
HUT72048A (en) 1996-03-28
BR9501404A (pt) 1996-03-05
EP1950200B1 (en) 2012-01-11
KR100368707B1 (ko) 2003-06-02
TW383302B (en) 2000-03-01

Similar Documents

Publication Publication Date Title
MY112897A (en) Ih-indole-3-glyoxylamide spla2 inhibitors
IL130338A0 (en) Pyrroles as sPLA2 inhibitors
EP0772596A4 (en) INDOLIZINE SPAL2 INHIBITORS
MX9804751A (es) Naftil acetamidas como inhibidores de la spla2.
IL130201A0 (en) Phenyl glyoxamides as spla2 inhibitors
EP1100492A4 (en) SPLA 2 INHIBITORS? INDOLE TYPE
MX9804750A (es) Naftil glioxamidas como inhibidores de la spla2.
AU5873400A (en) spla2 inhibitors
DE69910432D1 (de) Substituierte pyrroloindole
AU7053700A (en) Novel spla2 inhibitors